WO2000063403A3 - Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein - Google Patents

Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein Download PDF

Info

Publication number
WO2000063403A3
WO2000063403A3 PCT/NL2000/000247 NL0000247W WO0063403A3 WO 2000063403 A3 WO2000063403 A3 WO 2000063403A3 NL 0000247 W NL0000247 W NL 0000247W WO 0063403 A3 WO0063403 A3 WO 0063403A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
sequences encoding
human cell
human
encoding adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2000/000247
Other languages
French (fr)
Other versions
WO2000063403A2 (en
Inventor
Guus Hateboer
Karina Cornelia Verhulst
Govert Johan Schouten
Alphonsus Gerardus C Uytdehaag
Abraham Bout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Introgene BV
Original Assignee
Introgene BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000063403(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to HK03100323.5A priority Critical patent/HK1048138B/en
Priority to DE60018171T priority patent/DE60018171T3/en
Priority to NZ514951A priority patent/NZ514951A/en
Priority to AT00921175T priority patent/ATE289354T1/en
Priority to SI200030662T priority patent/SI1161548T2/en
Priority to AU41520/00A priority patent/AU772352B2/en
Priority to DK00921175.6T priority patent/DK1161548T4/en
Priority to PT00921175T priority patent/PT1161548E/en
Application filed by Introgene BV filed Critical Introgene BV
Priority to CA2370477A priority patent/CA2370477C/en
Priority to IL14584900A priority patent/IL145849A0/en
Priority to EP00921175A priority patent/EP1161548B2/en
Priority to JP2000612481A priority patent/JP4210036B2/en
Priority to MXPA01010360A priority patent/MXPA01010360A/en
Publication of WO2000063403A2 publication Critical patent/WO2000063403A2/en
Publication of WO2000063403A3 publication Critical patent/WO2000063403A3/en
Priority to IL145849A priority patent/IL145849A/en
Priority to NO20014977A priority patent/NO328951B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods and compositions for the production of recombinant proteins in a human cell line, using sequences encoding at least one E1 protein of an adenovirus where the cells does not encode a structural adenoviral protein from its genome. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, e.g. by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems like Chinese Hamster Ovary (CHO) cells.
PCT/NL2000/000247 1999-04-15 2000-04-17 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein Ceased WO2000063403A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
MXPA01010360A MXPA01010360A (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell.
DE60018171T DE60018171T3 (en) 1999-04-15 2000-04-17 USE OF ADENOVIRUS E1 PROTEIN ENCODING SEQUENCES FOR THE PREPARATION OF RECOMBINANT PROTEINS IN HUMAN CELLS.
NZ514951A NZ514951A (en) 1999-04-15 2000-04-17 Recombinant protein production in a cultured human cell
AT00921175T ATE289354T1 (en) 1999-04-15 2000-04-17 USE OF ADENOVIRUS E1 PROTEIN ENCODING SEQUENCES TO PRODUCE RECOMBINANT PROTEINS IN HUMAN CELLS.
SI200030662T SI1161548T2 (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
AU41520/00A AU772352B2 (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell
DK00921175.6T DK1161548T4 (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell using sequences encoding adenovirus E1 protein
PT00921175T PT1161548E (en) 1999-04-15 2000-04-17 PRODUCTION OF RECOMBINANT PROTEINS IN A HUMAN CELL USING SEQUENCES BY CODING ADENOVIRUS E1 PROTEIN
CA2370477A CA2370477C (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
HK03100323.5A HK1048138B (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
JP2000612481A JP4210036B2 (en) 1999-04-15 2000-04-17 Production of recombinant proteins in human cells
EP00921175A EP1161548B2 (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
IL14584900A IL145849A0 (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
IL145849A IL145849A (en) 1999-04-15 2001-10-10 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
NO20014977A NO328951B1 (en) 1999-04-15 2001-10-12 Method of Recombinant Production of Proteins in a Human Cell

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99201176 1999-04-15
EP99201176.7 1999-04-15
EP99204434.7 1999-12-21
EP99204434 1999-12-21

Publications (2)

Publication Number Publication Date
WO2000063403A2 WO2000063403A2 (en) 2000-10-26
WO2000063403A3 true WO2000063403A3 (en) 2001-02-15

Family

ID=26153302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2000/000247 Ceased WO2000063403A2 (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein

Country Status (18)

Country Link
EP (3) EP1533380B1 (en)
JP (1) JP4210036B2 (en)
CN (1) CN100457914C (en)
AT (3) ATE536417T1 (en)
AU (1) AU772352B2 (en)
CA (1) CA2370477C (en)
CY (1) CY1109759T1 (en)
DE (2) DE60018171T3 (en)
DK (3) DK1161548T4 (en)
ES (3) ES2378272T3 (en)
HK (1) HK1048138B (en)
IL (2) IL145849A0 (en)
MX (1) MXPA01010360A (en)
NO (1) NO328951B1 (en)
NZ (1) NZ514951A (en)
PT (2) PT1161548E (en)
SI (2) SI1161548T2 (en)
WO (1) WO2000063403A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871216B2 (en) 2005-04-06 2014-10-28 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8906378B2 (en) 2005-04-06 2014-12-09 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
WO2024043227A1 (en) 2022-08-23 2024-02-29 小野薬品工業株式会社 Bispecific antibody

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
WO2003048197A1 (en) * 2001-12-07 2003-06-12 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
EA008220B1 (en) 2001-10-29 2007-04-27 Круселл Холланд Б.В. Composition containing erythropoitin-like molecules and method of their use
ATE384785T1 (en) * 2001-12-07 2008-02-15 Crucell Holland Bv PRODUCTION OF VIRUSES, VIRUS ISOLATES, AND VACCINES
DK1456238T3 (en) * 2001-12-17 2008-08-18 Crucell Holland Bv Production of F (ab ') 2 fragments in mammalian cells
KR100454016B1 (en) * 2002-01-05 2004-10-26 한국과학기술원 Novel DHFR-deficient CHO cell line transfected with anti-apoptotic gene, method for preparation thereof and method for production of target proteins using the same
US7335490B2 (en) * 2002-01-09 2008-02-26 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
KR101017732B1 (en) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 Internalized anti-CD74 antibodies and methods of using the same
AU2002307635A1 (en) * 2002-04-19 2003-11-03 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
ES2524767T3 (en) 2002-06-14 2014-12-12 Immunomedics, Inc. HPAM4 humanized monoclonal antibody
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
KR101115797B1 (en) 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
NZ542585A (en) 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
DK1626992T3 (en) * 2003-05-23 2010-09-20 Crucell Holland Bv Production of recombinant IgM in PER.C6 cells
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
JP4733635B2 (en) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド Anti-CD19 antibody
EP1508576A1 (en) * 2003-08-20 2005-02-23 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
CN1863918B (en) 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 Packaging cells for recombinant adenoviruses
WO2005059149A2 (en) * 2003-12-12 2005-06-30 Chromagenics B.V. Improved protein production
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
PL1720972T3 (en) * 2004-03-05 2014-06-30 Dpx Holdings Bv Process for cell culturing by continuous perfusion and alternating tangential flow
PL2314621T3 (en) 2004-05-27 2014-08-29 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
JP4852046B2 (en) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー Binding molecules for the treatment and detection of cancer
BRPI0517380A (en) 2004-11-08 2008-10-07 Chromagenics Bv DNA molecule, expression cassette, host cell, and methods for generating a host cell expressing a polypeptide of interest and for producing a polypeptide of interest
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2006312148B2 (en) * 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR053416A1 (en) 2005-11-10 2007-05-09 Protech Pharma S A COMBINATION OF GLICOISOFORMS FOR THE TREATMENT OR PREVENTION OF SEPTICEMIA, TRANSGENIC CELLULAR LINE PRODUCING ERYTHROPOYETINE GLICOFORMES, PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMBINATION, PROCEDURES TO OBTAIN THE CELLULAR PROCEDURE
DE102005054628A1 (en) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Process for the preparation of permanent human cell lines
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
EP1996705B1 (en) 2006-03-20 2011-08-31 ChromaGenics B.V. Expression augmenting dna fragments, use thereof, and methods for finding thereof
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
DK2027155T3 (en) 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
FI2343362T4 (en) 2006-07-14 2024-07-04 Patheon Holdings I B V Improved process for the culturing of cells
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
SG10201607410TA (en) 2006-09-07 2016-10-28 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
JP2010512306A (en) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー Polypeptides with enhanced anti-inflammatory properties and reduced cytotoxic properties and related methods
EP3176263A1 (en) 2007-08-10 2017-06-07 Toto Ltd. Method of producing recombinant mammalian cells
CN101939330B (en) * 2007-12-13 2014-06-04 霍夫曼-拉罗奇有限公司 Novel rubella E1 envelope protein variants and their use in the detection of anti-rubella antibodies
US20120039939A1 (en) * 2008-04-11 2012-02-16 The Johns Hopkins University Compositions and methods for vaccine and virus production
JP2011517960A (en) 2008-04-22 2011-06-23 ザ ロックフェラー ユニバーシティー Method for identifying anti-inflammatory compounds
KR101639454B1 (en) * 2008-07-15 2016-07-13 크루셀 홀란드 비.브이. Scalable process for culturing per.c6 cells and producing products therefrom
CN102159243B (en) 2008-07-21 2015-08-19 免疫医疗公司 For the structural variant of the antibody for the treatment of feature improved
DK2421895T3 (en) 2009-04-23 2016-01-25 Crucell Holland Bv Recombinant human alpha 1-antitrypsin
KR101790354B1 (en) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
JP4998814B2 (en) 2009-10-01 2012-08-15 Ｔｏｔｏ株式会社 DNA construct and method for producing recombinant CHO cells using the same
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
ES2872081T3 (en) 2011-08-05 2021-11-02 Regeneron Pharma Humanized Universal Light Chain Mice
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN102827273A (en) * 2012-02-16 2012-12-19 张小莺 Preparation of vaccinia virus (VACA) resistant egg yolk antibody (IgY)
MX360056B (en) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof.
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US9657290B2 (en) 2012-07-03 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Scalable bio-element analysis
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
BR112015006824A2 (en) 2012-09-27 2017-07-04 Merus B V bispecific igg antibody, method for producing a bispecific igg antibody, antibody, pharmaceutical composition and use of a bispecific igg antibody
CA2884388A1 (en) 2012-09-27 2014-04-03 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof
AU2014255864B2 (en) 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
WO2014170258A1 (en) 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g proteins
WO2015000856A1 (en) 2013-07-01 2015-01-08 Charité - Universitätsmedizin Berlin Immortalized human chorion cell line and method for immortalizing human chorion cells
CN104693308B (en) * 2013-12-05 2020-08-04 同济大学 Smad5 protein that senses changes in intracellular pH and its application
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. Antibodies that bind egfr and erbb3
DK3805268T3 (en) 2014-02-28 2025-01-20 Merus Nv ANTIBODY THAT BINDS ERBB-2 AND ERBB-3
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
TWI743024B (en) 2014-06-06 2021-10-21 美商健臻公司 Perfusion culturing methods and uses thereof
US10174127B2 (en) 2015-02-05 2019-01-08 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
CA2975655C (en) 2015-02-05 2023-09-19 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
CN114277081A (en) 2015-02-22 2022-04-05 里兰斯坦福初级大学理事会 Micro-screening apparatus, method and product
CN107438622A (en) 2015-03-19 2017-12-05 瑞泽恩制药公司 Non-human animals selected for antigen-binding light chain variable regions
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
JP7296728B2 (en) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ Binding molecules that suppress cancer growth
US10703803B2 (en) 2016-03-01 2020-07-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza B neuraminidase
CN110198786A (en) 2016-11-14 2019-09-03 浩康生物系统公司 Method and apparatus for sorting target particles
CA3056517A1 (en) 2017-03-28 2018-10-04 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
JP7737220B2 (en) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ErbB-2 and ErbB3 binding bispecific antibodies for use in treating cells with NRG1 fusion genes - Patent Application 20070122999
CA3058290A1 (en) 2017-04-18 2018-10-25 Universite Libre De Bruxelles Biomarkers and targets for proliferative diseases
EP3625264B9 (en) 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
RS66708B9 (en) 2017-08-09 2025-08-29 Merus Nv Antibodies that bind egfr and cmet
EP3693013A4 (en) 2017-10-06 2021-06-30 Ono Pharmaceutical Co., Ltd. Bispecific antibody
AU2018380765A1 (en) 2017-12-04 2020-06-11 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
WO2019149798A1 (en) 2018-02-01 2019-08-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
TWI849895B (en) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 Bispecific antibody
JP7390729B2 (en) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Wnt signaling agonist molecules
TWI862565B (en) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 Bispecific antibody
JP6881658B2 (en) 2019-07-05 2021-06-02 小野薬品工業株式会社 Blood cancer treatment with PD-1 / CD3 bispecific protein
CA3149309A1 (en) 2019-07-30 2021-02-04 Ono Pharmaceutical Co., Ltd. Bispecific antibody
WO2021025140A1 (en) 2019-08-08 2021-02-11 小野薬品工業株式会社 Dual-specific protein
CN117441021A (en) * 2021-06-11 2024-01-23 孟山都技术有限公司 Methods and compositions for modifying protein accumulation
WO2026068859A1 (en) 2024-09-30 2026-04-02 Université Libre de Bruxelles Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185573A1 (en) * 1984-11-20 1986-06-25 Institut Pasteur Expression and excretion of polypeptides in eucaryotes under the control of an adenovirus promoter
WO1993003163A1 (en) * 1991-08-01 1993-02-18 Fondation Nationale De Transfusion Sanguine Expression in non-tumoral human lymphoblastoid lines with an integrative vector
WO1995029994A1 (en) * 1994-04-28 1995-11-09 Michigan State University Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (ad12/sv40) hybrid virus
WO1997000326A1 (en) * 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892737A (en) * 1988-09-22 1990-01-09 University Of Florida Composition and method for enhancing permeability of topical drugs
GB8900483D0 (en) * 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
CA2144040A1 (en) * 1993-07-13 1995-01-26 Michel Perricaudet Defective adenovirus vectors and use thereof in gene therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185573A1 (en) * 1984-11-20 1986-06-25 Institut Pasteur Expression and excretion of polypeptides in eucaryotes under the control of an adenovirus promoter
WO1993003163A1 (en) * 1991-08-01 1993-02-18 Fondation Nationale De Transfusion Sanguine Expression in non-tumoral human lymphoblastoid lines with an integrative vector
WO1995029994A1 (en) * 1994-04-28 1995-11-09 Michigan State University Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (ad12/sv40) hybrid virus
WO1997000326A1 (en) * 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOUT, A. (1) ET AL: "Improved helper cells for RCA-free production of E1-deleted recombinant adenovirus vectors.", CANCER GENE THERAPY, (1996) VOL. 3, NO. 6 CONF. SUPPL., PP. S24. MEETING INFO.: FIFTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER SAN DIEGO, CALIFORNIA, USA NOVEMBER 14-16, 1996, XP002115718 *
BOUT, A. ET AL: "Production of RCA-free batches of E1-deleted recombinant adenoviral vectors on PER. C6", NUCLEIC ACIDS SYMP. SER. (1998), 38(ADVANCES IN GENE TECHNOLOGY: MOLECULA BIOLOGY IN THE CONQUEST OF DISEASE), 35-36, 1998, XP002115716 *
BOUTL, A. (1) ET AL: "A novel packaging cell line ( PER. C6 ) for efficient production of RCA-free batches of E1-deleted recombinant adenoviral vectors.", CANCER GENE THERAPY, (NOV.-DEC., 1997) VOL. 4, NO. 6 CONF. SUPPL., PP. S32-S33. MEETING INFO.: SIXTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER SAN DIEGO, CALIFORNIA, USA NOVEMBER 20-22, 1997, XP002115717 *
FALLAUX, FRITS J. ET AL: "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.", HUMAN GENE THERAPY, (SEPT. 1, 1998) VOL. 9, NO. 13, PP. 1909-1917., XP002115715 *
GRAND R J A ET AL: "MODULATION OF THE LEVEL OF EXPRESSION OF CELLULAR GENES IN ADENOVIRUS 12-INFECTED AND TRANSFORMED HUMAN CELLS.", EMBO (EUR MOL BIOL ORGAN) J, (1986) 5 (6), 1253-1260., XP002115719 *
GRAND, ROGER J. A. (1) ET AL: "The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.", VIROLOGY, (1995) VOL. 210, NO. 2, PP. 323-334., XP002115720 *
YU, DIHUA ET AL: "Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A", CANCER RES. (1993), 53(4), 891-8, 1993, XP002115721 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871216B2 (en) 2005-04-06 2014-10-28 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8906378B2 (en) 2005-04-06 2014-12-09 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
US9359443B2 (en) 2005-04-06 2016-06-07 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases
WO2024043227A1 (en) 2022-08-23 2024-02-29 小野薬品工業株式会社 Bispecific antibody

Also Published As

Publication number Publication date
SI1161548T1 (en) 2005-08-31
CN1360638A (en) 2002-07-24
IL145849A (en) 2009-07-20
DE60018171T2 (en) 2005-12-29
AU4152000A (en) 2000-11-02
PT1161548E (en) 2005-06-30
ES2335775T3 (en) 2010-04-05
CA2370477A1 (en) 2000-10-26
JP2002541854A (en) 2002-12-10
NO20014977D0 (en) 2001-10-12
DE60043273D1 (en) 2009-12-17
DE60018171D1 (en) 2005-03-24
EP2163640A1 (en) 2010-03-17
EP1161548B2 (en) 2009-10-14
SI1161548T2 (en) 2010-02-26
DK1161548T4 (en) 2010-03-01
PT1533380E (en) 2010-02-09
NO20014977L (en) 2001-12-17
NZ514951A (en) 2004-02-27
DK1533380T3 (en) 2010-02-01
AU772352B2 (en) 2004-04-22
IL145849A0 (en) 2002-07-25
HK1048138A1 (en) 2003-03-21
MXPA01010360A (en) 2004-04-05
ATE536417T1 (en) 2011-12-15
SI1533380T1 (en) 2010-03-31
ATE289354T1 (en) 2005-03-15
DE60018171T3 (en) 2010-05-20
DK2163640T3 (en) 2012-03-05
CA2370477C (en) 2010-06-29
WO2000063403A2 (en) 2000-10-26
ATE447617T1 (en) 2009-11-15
CN100457914C (en) 2009-02-04
HK1048138B (en) 2009-06-12
EP1161548B1 (en) 2005-02-16
NO328951B1 (en) 2010-06-28
DK1161548T3 (en) 2005-05-23
ES2237420T3 (en) 2005-08-01
EP1533380A3 (en) 2005-06-22
JP4210036B2 (en) 2009-01-14
EP1533380A2 (en) 2005-05-25
EP1533380B1 (en) 2009-11-04
CY1109759T1 (en) 2014-09-10
EP2163640B1 (en) 2011-12-07
ES2378272T3 (en) 2012-04-10
ES2237420T5 (en) 2010-03-03
EP1161548A2 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
NZ514951A (en) Recombinant protein production in a cultured human cell
SI0866876T1 (en) Process for the preparation of recombinant proteins in e.coli by high cell density fermentation
CA2400908A1 (en) Fusion protein having enhanced in vivo erythropoietin activity
WO2004061122A3 (en) Cell proliferation-related polypeptides and uses therefor
AU3802595A (en) Tripeptidyl aminopeptidase
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU2658200A (en) Oxaloacetate hydrolase deficient fungal host cells
Wolf et al. Determination of the carbohydrate composition and the disulfide bond linkages of bovine lactoperoxidase by mass spectrometry
WO1997006247A3 (en) Deubiquitinating enzymes that regulate cell growth
DE60117998D1 (en) MUTATE FURINE POLYPEPTIDE, WHICH HAVE IMPROVED PROPERTIES
AU5776799A (en) Modified hcv peptide vaccines
WO2004034780A3 (en) Method of producing recombinant proteins in the mammary gland of non-transgenic mammals
EP1549675A4 (en) INTERFERON ISO ALPHA HUMAN GLYCOSYL
WO2002085922A3 (en) Proteins and nucleic acids encoding same
WO2005012341A3 (en) Pichia methanolica secretory signal
GB9930359D0 (en) Novel polypeptides
WO1998051788A3 (en) Method and construct for inhibition of cell migration
WO2000000506A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO2000032777A3 (en) Scorpion toxins
CA2422295A1 (en) A gene of aluminum-activated malate transporter of a plant and a protein encoded by the gene
SE9901339D0 (en) New expression systems
WO2004031731A3 (en) Methods for controlling proliferation of cells
WO2002057305A3 (en) A gene whose expression promotes differentiation of myeloid progenitor cells into neutrophils and/or monocytes/macrophages
WO2002070660A3 (en) Proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808938.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2000921175

Country of ref document: EP

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2370477

Country of ref document: CA

Ref document number: 2370477

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010360

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 612481

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 514951

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2000921175

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000921175

Country of ref document: EP